Related Experiment Video
Updated: May 10, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Crizotinib-associated nodular scleritis in an adolescent.
Mennatullah Elfwwal1, Douglas S Hawkins2, Laura C Huang1
1Department of Ophthalmology, University of Washington, Seattle, Washington; Division of Ophthalmology, Seattle Children's Hospital, Seattle, Washington.
Crizotinib therapy for anaplastic large-cell lymphoma may cause scleritis, an eye inflammation. Discontinuing the drug resolved the condition, suggesting a link between crizotinib and this ocular side effect.
Area of Science:
- Ophthalmology
- Oncology
- Pharmacology
Background:
- Anaplastic large-cell lymphoma (ALCL) is a type of non-Hodgkin lymphoma.
- Crizotinib is an anaplastic lymphoma kinase (ALK) inhibitor used in ALCL treatment.
- Scleritis is a serious inflammatory eye condition.
More Related Videos
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
06:15Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia
Published on: August 9, 2024